Abstract:ID 96214 Poster Board 484 Statement of the Problem . Epilepsy is the 4 th common neurological disorder after Parkinson's and Alzheimer's Disease and Stroke, with 3 million people in the US and 65 million people worldwide living with epilepsy. At the molecular level, it is known that voltage-gated sodium (VGSC) and calcium channels are related to the onset of seizures. Our lab engages in early drug design and discovery of novel small molecules as potential anti-seizure analogs, for epilepsy. Previous hit-to-lead optimization and target identification studies performed by our research team, led to the discovery of lead compound, ETSP 518001.This analog has been shown to act as a potent and selective Ca v 3.2 and Ca v 3.3 T-type voltage-gated calcium channel (T-VGCC) inhibitor. The objective of the work presented is to evaluate the inhibitory effects of several novel enaminone derivatives based on the prototype ETSP 518001 to identify new lead compounds as T-VGCC inhibitors. Methods: To design the novel enaminone derivatives, we utilized MedChem Studio, a simulation program to determine the druggability of the desired small molecules. Preliminary in vitro whole cell patch clamp experiments were performed to assess the inhibitory effects of several target analogs on voltage-activated Ca 2+ currents in human embryonic kidney (HEK-293) cells. Cav3.2 transfected HEK 293 cells were treated with 50 μM of test compounds and compared to the control group (none pretreated HEK 293 cells). Statistical analyses consisted of t-test for pairwise comparisons or one-way ANOVA followed by post hoc analysis using Tukey's honest significant difference test for comparisons between multiple groups. To validate the biological activity, studies were conducted at the National Institutes of Neurological Disorders and Stroke Epilepsy Therapy Screening Program, NIH. ETSP 578001 was investigated in acute rodent seizure models, to determine the efficacy and safety as an anti-seizure agent. Results. Each enaminone analog in our novel series were examined in MedChem studio and were calculated to have an average CLogP value of 2.96, and predicted to have high blood brain barrier permeability (99%). Preliminary in vitro studies showed ETSP 578001 has ≥ 90% inhibition of T-VGCC current, generated by the Ca v 3.2 subunit. Enaminone analog RHB62 caused a reduction in the Ca 2+ current, with lower potency than ETSP 578001. No inhibitory effect was shown at a similar concentration for analogs RHB59, RHB95 or RHB103. Further research showed that ETSP 578001 analog also inhibited VGSCs and had no effect on cell viability. These results show that ETSP 578001 had dual inhibition properties. Results from the preclinical in vivo study demonstrated that compound ETSP 587001 had low efficacy in the 6Hz 44 mA and the maximal electroshock (MES) rodent seizure model, as 0/4 animals were protected at pretreatment times 0.5h and 2h. Conclusion: A target-based drug design strategy was employed, that led to the discovery of ETSP 578001, as a dual VGSC and T-VGCC blocker. This analog showed toxicity in the ETSP rodent seizure model. Future studies will involve lead optimization and target identification studies on ETSP 578001. PhRMA Foundation, Pre-Doctoral Fellowship in Drug Discovvery University of Maryland Eastern Shore Richard A. Bernstein Endowment

Discovery of triazenyl triazoles as Na<sub>v</sub>1.1 channel blockers for treatment of epilepsy

Discovery of Novel Pyrimidine-Based Derivatives as Nav1.2 Inhibitors with Efficacy in Mouse Models of Epilepsy

Discovery of Potent and Selective Blockers Targeting the Epilepsy-Associated K Na 1.1 Channel

Discovery of Potent and Selective Blockers Targeting the Epilepsy-Associated KNa1.1 Channel.

Tuning Sodium Channel Blockers to the Near-Atomic Level

Inhibition of resurgent Na+ currents by rufinamide

Discovery of 7-alkyloxy- [1,2,4] triazolo[1,5-a] pyrimidine derivatives as selective positive modulators of GABAA1 and GABAA4 receptors with potent antiepileptic activity

Isoform-specific Prolongation of Kv7 (KCNQ) Potassium Channel Opening Mediated by New Molecular Determinants for Drug-Channel Interactions

Molecular Pharmacology of Selective Na V 1.6 and Dual Na V 1.6/Na V 1.2 Channel Inhibitors that Suppress Excitatory Neuronal Activity Ex Vivo

A Combined Ligand- and Structure-Based Virtual Screening To Identify Novel NaV1.2 Blockers: In Vitro Patch Clamp Validation and In Vivo Anticonvulsant Activity

Dual-pocket Inhibition of Navchannels by the Antiepileptic Drug Lamotrigine

Electrophysiological and Pharmacological Characterization of a Novel and Potent Neuronal Kv7 Opener SCR2682 for Anti-Epilepsy

Development of new chiral 1,2,4-triazole-3-thiones and 1,3,4-thiadiazoles with promising in vivo anticonvulsant activity targeting GABAergic system and voltage-gated sodium channels (VGSCs)

XEN1101: A Novel Potassium Channel Modulator for the Potential Treatment of Focal Epilepsy in Adults

Design, synthesis, biological evaluation, homology modeling and docking studies of (E)-3-(benzo[d][1,3]dioxol-5-ylmethylene) pyrrolidin-2-one derivatives as potent anticonvulsant agents

Identification of a New Retigabine Derivative with Improved Photostability for Selective Activation of Neuronal Kv7 Channels and Antiseizure Activity.

The Drug Design and Discovery of Novel Enaminone Derivatives as Potential Anti-seizure Agents

An assessment of rufinamide as an anti-epileptic in comparison with other drugs in clinical development

1,2,4-triazole derivatives as potential scaffold for anticonvulsant activity

Trpv1: A Potential Target for Antiepileptogenesis

Searching for New Leads To Treat Epilepsy: Target-Based Virtual Screening for the Discovery of Anticonvulsant Agents